Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $103M | $14.1M | $45.6M | $22.5M |
| Revenue growth | — | — | -86.3% | 223.4% | -50.6% |
| Operating income | -$35.0M | -$3.56M | -$183M | -$176M | -$226M |
| Operating margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Net income | -$41.8M | -$22.6M | -$177M | -$242M | -$204M |
| Net margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (diluted) | -$3.81 | -$1.19 | -$2.15 | -$2.56 | -$1.72 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$29.5M | $10.7M | -$141M | -$159M | -$148M |
| Capital expenditures | $24.0K | $221K | $24.0K | $672K | $246K |
| Free cash flow | -$29.5M | $10.4M | -$141M | -$159M | -$148M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | — | — | $340M | $772M | $490M |
| Total assets | — | $478M | $347M | $865M | $769M |
| Total liabilities | — | $48.4M | $58.7M | $107M | $85.9M |
| Shareholders' equity | -$114M | $430M | $288M | $758M | $683M |
| Retained earnings | — | -$140M | -$317M | -$559M | -$762M |
| Shares (wtd avg diluted) | 11.0M | 19.0M | 82.2M | 94.4M | 118M |
Every figure is extracted from NewAmsterdam Pharma Co N.V.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.